Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Date:6/4/2008

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Wednesday, June 11, 2008 at 3:00 pm Eastern Time (12:00 pm Pacific Time) during the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference at the New York Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
2. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
3. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
4. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
5. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
8. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... Driving Dynamics Inc., announced today it has been selected as ... part of its mission to continually monitor the training marketplace for the best providers ... 20 Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard ... businesses and organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released ... own QMS, with a deadline of September 2018. , As described in ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone ... launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is ... the U.S. to incorporate magnesium, a critical property for bone health and development. ...
(Date:9/19/2017)... ... , ... First Choice Emergency Room , the largest network of independent ... Medical Director of its Pflugerville- FM 685 facility. , “We are pleased to ... 685 location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the country with the Davidson Fellows Scholarship on September 27 at a reception ... in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: